RT @CD_AACR@twitter.com

Check out the paper featured on this month's cover:
Creating MHC-restricted #Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy, by Takamitsu Hattori, @LorenzoMaso1@twitter.com, @DrBenNeel@twitter.com, Shohei Koide et al.
https://bit.ly/3XbM7Qm
@Perlmutter_CC@twitter.com @nyulangone@twitter.com

🐦🔗: https://twitter.com/CD_AACR/status/1612866303701782548

Excited to share our work of the of the last 5 years. https://www.biorxiv.org/content/10.1101/2023.01.06.523012v1. We found that in response to the ISR, the primate-specific #lncRNA LISR customises the #ribosomes to drive translation of an immune suppressive signature. The signature includes #neoantigens translated from lncRNAs, the #immunecheckpoint receptor PDL1 and the #glycocalyx. LISR KD restores sensitivity to #immunecheckpointblockade in #melanoma and possibly in other cancers.